(Q33784011)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Liver involvement in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

0 references

Pier Maria Battezzati

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

C Colombo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Crosignani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

946-954

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

The changing epidemiology of cystic fibrosis

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Cystic fibrosis: molecular biology and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Regulation of plasma membrane recycling by CFTR.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Pancreatitis and mutations of the cystic fibrosis gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Genotype-phenotype correlations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (delta-f508) cystic fibrosis transmembrane conductance regulator

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

The role of hepatobiliary scintigraphy in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Hepatoprotective properties of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Growth factor and procollagen type I gene expression in human liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Analysis of risk factors for the development of liver disease associated with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Clinical and genetic risk factors for cystic fibrosis-related liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver disease and common-bile-duct stenosis in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver disease and bile duct abnormalities in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Biliary complications of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Prevalence of liver disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Hepatobiliary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver and biliary problems in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Gallstones in cystic fibrosis: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Bile acid metabolism in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Fasting serum bile acid levels in relation to liver histopathology in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Duration of mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Magnetic resonance cholangiography: comparison with endoscopic retrograde cholangiopancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

New pharmaceutical approaches to the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Clinical pharmacokinetics of therapeutic bile acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Adenosine triphosphate activates ion permeabilities in biliary epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Paradoxical effects of essential fatty acid supplementation on lipid profiles and sweat electrolytes in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Excessive Fecal Taurine Loss Predisposes to Taurine Deficiency in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Bleeding gastroesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

The management of portal hypertension in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic shunt placement

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Cystic fibrosis and portal hypertension interest of partial splenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

Liver cirrhosis in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980299-2

7 January 2021

10.1016/S0168-8278(99)80299-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10580595%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference